What is the 13F Pro Quality Score for IMNM?

13F Pro ranks Immunome Inc. (IMNM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMNM's current score at https://13fpro.ai/research/IMNM (free sign-up required for the full ranking).

Which hedge funds own the most IMNM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMNM include FMR, BlackRock,, Redmile Group,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IMNM as soon as new 13F filings post.

Where does 13F Pro source IMNM data?

All Immunome Inc. fundamentals and ownership data come directly from SEC EDGAR. Immunome Inc. files with the SEC under CIK 1472012. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMNM in?

Immunome Inc. (IMNM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMNM research updated on 13F Pro?

IMNM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immunome Inc.(IMNM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1472012 IMNM stock profile & AI dashboard →

13F Pro Quality Score

5.8/100

Rank #2,844 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.9/100

Profitability

1.3/100

Balance Sheet

7.9/100

Earnings Quality

30.0/100

Free Cash Flow

1.1/100

Institutional Flow

20.0/100

Revenue Scale

2.7/100

Dilution Risk

1.3/100

IMNM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Immunome Inc. (IMNM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMNM at 5.8/100 on a 32-signal composite quality model, placing it at rank #2,844 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.1) and profitability (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Immunome Inc. reports net income of $-53.8M, free cash flow of $-61.6M. Top institutional holders of IMNM by reported 13-F value include FMR, BlackRock,, Redmile Group,, based on the most recent SEC filings. IMNM trades on the Nasdaq exchange and files with the SEC under CIK 1472012. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunome Inc. directly from SEC EDGAR. Immunome Inc.'s 13F Pro composite quality score has ranged between 6 and 37 since 2024, currently 5.8 — a declining long-term trajectory across 32 quarterly and live scoring snapshots.

✦

Fun facts about Immunome Inc.

Quirks, history, and lore behind IMNM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · focused on oncology · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
A micro-cap with minimal revenue and a pipeline still working its way through clinical trials — the business model is science first, profits (much) later.
3
The History
Founded in the 2010s, the company was rebuilt around a bold idea: use memory B-cell technology to find antibody drug candidates the human immune system already knows how to make.
4
The Secret
Its platform essentially interrogates cancer survivors' immune cells to discover which antibodies their bodies naturally deployed — then turns those into drugs.
5
The Lore
The company inked a collaboration deal with Pfizer to co-develop cancer antibody therapies, a partnership that put a small Maryland biotech on much bigger radar screens.
6
The Giveaway
Its very name is a mashup of "immune" and "genome" — and its ticker is a tidy four-letter advertisement for what it does: IMNM.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-53.8M

Free Cash Flow

Q1 2026

$-61.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-23.2% YoY

$6.9MFY 2025

FY20 —FY22 —FY24 $9.0MFY25 $6.9M

Net Income

+27.5% YoY

$-212.4MFY 2025

FY20 $-17.8MFY22 $-36.9MFY24 $-293.0MFY25 $-212.4M

Operating Income

+26.7% YoY

$-224.1MFY 2025

FY20 $-12.3MFY22 $-36.9MFY24 $-305.8MFY25 $-224.1M

EPS (Diluted)

+51.4% YoY

$-2.43FY 2025

FY20 $-5.26FY22 $-3.09FY24 $-5.00FY25 $-2.43

Total Assets

+184.4% YoY

$683.2MFY 2025

FY20 $44.5MFY22 $24.0MFY24 $240.2MFY25 $683.2M

Total Debt

—FY 2025

FY20 $866.0KFY22 —FY24 —FY25 —

Op. Cash Flow

-72.3% YoY

$-190.9MFY 2025

FY20 $-12.1MFY22 $-28.7MFY24 $-110.8MFY25 $-190.9M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$6.9M -23.2%	$9.0M	—	—	—	—
Net Income	$-212.4M +27.5%	$-293.0M -694.0%	$-36.9M -106.9%	$-17.8M -70.8%	$-10.4M	—
Operating Income	$-224.1M +26.7%	$-305.8M -728.7%	$-36.9M -201.0%	$-12.3M -18.5%	$-10.3M	—
EPS (Diluted)	$-2.43 +51.4%	$-5.00 -61.8%	$-3.09 +41.3%	$-5.26	—	—
Total Assets	$683.2M +184.4%	$240.2M +899.1%	$24.0M -46.0%	$44.5M +779.9%	$5.1M	—
Total Debt	—	—	—	$866.0K	—	—
Operating Cash Flow	$-190.9M -72.3%	$-110.8M -286.2%	$-28.7M -136.4%	$-12.1M -26.4%	$-9.6M	—

AI Insight: IMNM Financial Trends

Immunome is burning cash with zero revenue, equity dilution accelerating sharply in recent quarters.

• Revenue collapsed to $0M in Q3 2025 and Q4 2025, down from $4M in Q2 2025; no recovery in Q1 2026.

• Operating cash burn intensified to $59M in Q1 2026, highest on record; Q4 2025 at $48M.

• Equity surged to $634M in Q4 2025 from $264M in Q3 2025—likely capital raise diluting existing shareholders.

⚠ Quarterly net losses now $54M–$70M with zero top-line traction; cash runway critical without further funding.

⚠ Operating margin worsened to –∞ as revenue hit zero; cost structure not adjusting to revenue cliff.

AI Insight: IMNM Ratio Trends

Immunome remains deeply unprofitable, but loss severity narrowed sharply from Q4 2024 lows; ROE improved to -36.6% in Q1 2026.

• ROE improved from -177.2% in Q4 2024 to -36.6% in Q1 2026, signaling reduced per-quarter loss magnitude.

• ROIC deterioration through Q3 2025 (-91.1%) has reversed; Q1 2026 ROIC of -40.3% matches TTM level.

⚠ Company remains unprofitable across all quarters shown; no path to profitability visible in available data.

⚠ Q4 2024 represented an extreme loss quarter (ROE -177.2%); clarify whether it was a one-time charge or structural issue.

Get alerted when IMNM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immunome Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMNM

FMR LLC
$371.1M16,969,954 sh
BlackRock, Inc.
$178.6M8,168,674 sh
Redmile Group, LLC
$121.6M5,558,885 sh
STATE STREET CORP
$118.1M5,399,901 sh
PRIMECAP MANAGEMENT CO/CA/
$104.7M4,788,231 sh
WELLINGTON MANAGEMENT GROUP LLP
$103.5M4,731,977 sh
VANGUARD CAPITAL MANAGEMENT LLC
$96.9M4,429,697 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$89.7M4,099,901 sh
Enavate Sciences GP, LLC
$79.0M3,613,799 sh
MORGAN STANLEY
$62.1M2,841,589 sh

Fund	Value	Shares
FMR LLC	$371.1M	16,969,954
BlackRock, Inc.	$178.6M	8,168,674
Redmile Group, LLC	$121.6M	5,558,885
STATE STREET CORP	$118.1M	5,399,901
PRIMECAP MANAGEMENT CO/CA/	$104.7M	4,788,231
WELLINGTON MANAGEMENT GROUP LLP	$103.5M	4,731,977
VANGUARD CAPITAL MANAGEMENT LLC	$96.9M	4,429,697
DRIEHAUS CAPITAL MANAGEMENT LLC	$89.7M	4,099,901
Enavate Sciences GP, LLC	$79.0M	3,613,799
MORGAN STANLEY	$62.1M	2,841,589

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMNM on your watchlist

Track score changes the day Immunome Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMNM a good stock to buy?

13F Pro's AI-powered analysis of Immunome Inc. (IMNM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMNM are available on the IMNM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMNM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMNM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immunome Inc.'s investment landscape.